\relax 
\providecommand\hyper@newdestlabel[2]{}
\providecommand\BKM@entry[2]{}
\providecommand\HyperFirstAtBeginDocument{\AtBeginDocument}
\HyperFirstAtBeginDocument{\ifx\hyper@anchor\@undefined
\global\let\oldcontentsline\contentsline
\gdef\contentsline#1#2#3#4{\oldcontentsline{#1}{#2}{#3}}
\global\let\oldnewlabel\newlabel
\gdef\newlabel#1#2{\newlabelxx{#1}#2}
\gdef\newlabelxx#1#2#3#4#5#6{\oldnewlabel{#1}{{#2}{#3}}}
\AtEndDocument{\ifx\hyper@anchor\@undefined
\let\contentsline\oldcontentsline
\let\newlabel\oldnewlabel
\fi}
\fi}
\global\let\hyper@last\relax 
\gdef\HyperFirstAtBeginDocument#1{#1}
\providecommand\HyField@AuxAddToFields[1]{}
\providecommand\HyField@AuxAddToCoFields[2]{}
\bibstyle{WileyNJD-AMA}
\BKM@entry{id=1,open,dest={446F632D5374617274},srcline={69}}{412053747275637475726564204672616D65776F726B20666F722041646170746976656C7920496E636F72706F726174696E672045787465726E616C2045766964656E636520696E2053657175656E7469616C6C79204D6F6E69746F72656420436C696E6963616C20547269616C73}
\BKM@entry{id=2,open,dest={446F632D5374617274},srcline={69}}{4162737472616374}
\BKM@entry{id=3,open,dest={73656374696F6E2E31},srcline={73}}{496E74726F64756374696F6E}
\citation{FDA2006}
\citation{Jennison2000}
\citation{Spiegelhalter1993}
\@writefile{toc}{\contentsline {chapter}{A Structured Framework for \leavevmode {\color  {blue}Adaptively Incorporating External Evidence in Sequentially Monitored Clinical Trials}}{1}{Doc-Start}\protected@file@percent }
\Newlabel{1}{1}
\Newlabel{2}{2}
\@writefile{toc}{\contentsline {section}{Abstract}{1}{Doc-Start}\protected@file@percent }
\citation{FDA2017}
\citation{FDA_CID}
\citation{USCongress2016}
\@writefile{toc}{\contentsline {section}{\numberline {1}Introduction}{2}{section.1}\protected@file@percent }
\citation{Ventz2015,Zhu2015}
\citation{Stallard2020,Kopp-Schneider2020,Zhu2019}
\citation{Psioda2018}
\BKM@entry{id=4,open,dest={73656374696F6E2E32},srcline={207}}{4D6574686F6473}
\BKM@entry{id=5,open,dest={73756273656374696F6E2E322E31},srcline={209}}{5072656C696D696E6172696573}
\BKM@entry{id=6,open,dest={73756273756273656374696F6E2E322E312E31},srcline={210}}{426179657369616E204879706F7468657369732054657374696E67}
\BKM@entry{id=7,open,dest={73756273756273656374696F6E2E322E312E32},srcline={248}}{466F726D616C697A696E672074686520537461746973746963616C20436F6E63657074206F66206120436F6D70656C6C696E672044656D6F6E7374726174696F6E}
\@writefile{toc}{\contentsline {section}{\numberline {2}Methods}{4}{section.2}\protected@file@percent }
\newlabel{sec:methods}{{2}{4}{Methods}{section.2}{}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.1}Preliminaries}{4}{subsection.2.1}\protected@file@percent }
\newlabel{sec:preliminaries}{{2.1}{4}{Preliminaries}{subsection.2.1}{}}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {2.1.1}Bayesian Hypothesis Testing}{4}{subsubsection.2.1.1}\protected@file@percent }
\@writefile{toc}{\contentsline {subsubsection}{\numberline {2.1.2}Formalizing the Statistical Concept of a Compelling Demonstration}{4}{subsubsection.2.1.2}\protected@file@percent }
\newlabel{sec:sub_evid}{{2.1.2}{4}{Formalizing the Statistical Concept of a Compelling Demonstration}{subsubsection.2.1.2}{}}
\BKM@entry{id=8,open,dest={73756273756273656374696F6E2E322E312E33},srcline={274}}{536B6570746963616C20616E6420456E74687573696173746963204D6F6E69746F72696E67205072696F7273}
\newlabel{eq:compellingevidence}{{2}{5}{Formalizing the Statistical Concept of a Compelling Demonstration}{equation.2.2}{}}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {2.1.3}Skeptical and Enthusiastic Monitoring Priors}{5}{subsubsection.2.1.3}\protected@file@percent }
\newlabel{sec:MP}{{2.1.3}{5}{Skeptical and Enthusiastic Monitoring Priors}{subsubsection.2.1.3}{}}
\BKM@entry{id=9,open,dest={73756273756273656374696F6E2E322E312E34},srcline={336}}{4D6178696D756D2053616D706C652053697A6520616E6420466F726D616C2053746F7070616765204372697465726961}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {2.1.4}Maximum Sample Size and Formal Stoppage Criteria}{6}{subsubsection.2.1.4}\protected@file@percent }
\BKM@entry{id=10,open,dest={73756273656374696F6E2E322E32},srcline={396}}{53706563696679696E67204D6F6E69746F72696E67205072696F7273}
\BKM@entry{id=11,open,dest={73756273756273656374696F6E2E322E322E31},srcline={397}}{44656661756C74204D6F6E69746F72696E67205072696F7273}
\citation{LeCam2000}
\BKM@entry{id=12,open,dest={73756273756273656374696F6E2E322E322E32},srcline={420}}{47656E6572616C697A6564204E6F726D616C20446973747269627574696F6E}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.2}Specifying Monitoring Priors}{7}{subsection.2.2}\protected@file@percent }
\newlabel{sec:mps}{{2.2}{7}{Specifying Monitoring Priors}{subsection.2.2}{}}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {2.2.1}Default Monitoring Priors}{7}{subsubsection.2.2.1}\protected@file@percent }
\@writefile{toc}{\contentsline {subsubsection}{\numberline {2.2.2}Generalized Normal Distribution}{7}{subsubsection.2.2.2}\protected@file@percent }
\newlabel{sec:gen_normal}{{2.2.2}{7}{Generalized Normal Distribution}{subsubsection.2.2.2}{}}
\citation{Nadarajah2005}
\BKM@entry{id=13,open,dest={73756273756273656374696F6E2E322E322E33},srcline={531}}{496E636F72706F726174696E67205072696F7220496E666F726D6174696F6E20696E20746865204D6F6E69746F72696E67205072696F7273}
\@writefile{lof}{\contentsline {figure}{\numberline {1}{\ignorespaces A, Default skeptical prior. B, Concentrated skeptical prior. C, Default enthusiastic prior. D, Flattened enthusiastic prior.\relax }}{9}{figure.caption.1}\protected@file@percent }
\providecommand*\caption@xref[2]{\@setref\relax\@undefined{#1}}
\newlabel{fig:figure1}{{1}{9}{A, Default skeptical prior. B, Concentrated skeptical prior. C, Default enthusiastic prior. D, Flattened enthusiastic prior.\relax }{figure.caption.1}{}}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {2.2.3}Incorporating Prior Information in the Monitoring Priors}{9}{subsubsection.2.2.3}\protected@file@percent }
\newlabel{sec:incorporating}{{2.2.3}{9}{Incorporating Prior Information in the Monitoring Priors}{subsubsection.2.2.3}{}}
\citation{Box1980}
\BKM@entry{id=14,open,dest={73756273756273656374696F6E2E322E322E34},srcline={625}}{5072696F722053706563696669636174696F6E20666F72204E756973616E636520506172616D6574657273}
\newlabel{eq:inference_prior}{{3}{10}{Incorporating Prior Information in the Monitoring Priors}{equation.2.3}{}}
\newlabel{eq:pred_dist}{{4}{10}{Incorporating Prior Information in the Monitoring Priors}{equation.2.4}{}}
\newlabel{eq:box_p}{{5}{10}{Incorporating Prior Information in the Monitoring Priors}{equation.2.5}{}}
\newlabel{eq:omega}{{6}{10}{Incorporating Prior Information in the Monitoring Priors}{equation.2.6}{}}
\BKM@entry{id=15,open,dest={73656374696F6E2E33},srcline={693}}{4578616D706C6573}
\BKM@entry{id=16,open,dest={73756273656374696F6E2E332E31},srcline={695}}{53696E676C652D41726D2050726F6F662D6F662D416374697669747920547269616C20776974682042696E61727920456E64706F696E74}
\BKM@entry{id=17,open,dest={73756273756273656374696F6E2E332E312E31},srcline={696}}{4D6F7469766174696E67204578616D706C65}
\citation{Hyams2012}
\citation{Rutgeerts2005}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {2.2.4}Prior Specification for Nuisance Parameters}{11}{subsubsection.2.2.4}\protected@file@percent }
\newlabel{sec:cond_marg}{{2.2.4}{11}{Prior Specification for Nuisance Parameters}{subsubsection.2.2.4}{}}
\@writefile{toc}{\contentsline {section}{\numberline {3}Examples}{11}{section.3}\protected@file@percent }
\newlabel{sec:examples}{{3}{11}{Examples}{section.3}{}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.1}Single-Arm Proof-of-Activity Trial with Binary Endpoint}{11}{subsection.3.1}\protected@file@percent }
\newlabel{sec:example1}{{3.1}{11}{Single-Arm Proof-of-Activity Trial with Binary Endpoint}{subsection.3.1}{}}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {3.1.1}Motivating Example}{11}{subsubsection.3.1.1}\protected@file@percent }
\BKM@entry{id=18,open,dest={73756273756273656374696F6E2E332E312E32},srcline={715}}{4D6F64656C20466F726D756C6174696F6E205C303436205072696F7220456C696369746174696F6E}
\@writefile{lof}{\contentsline {figure}{\numberline {2}{\ignorespaces A, Concentrated skeptical prior $\pi _S(\theta )$ truncated to $[-1,1]$. B, Conditional prior $\pi (\eta |\theta =\theta _0)$. C, Joint prior $\pi (\theta ,\eta )=\pi (\theta )\times \pi (\eta |\theta )$ truncated based on the conditions $-1<\theta <1$ and $0<\theta +\eta <1$.\relax }}{12}{figure.caption.2}\protected@file@percent }
\newlabel{fig:figure5}{{2}{12}{A, Concentrated skeptical prior $\pi _S(\theta )$ truncated to $[-1,1]$. B, Conditional prior $\pi (\eta |\theta =\theta _0)$. C, Joint prior $\pi (\theta ,\eta )=\pi (\theta )\times \pi (\eta |\theta )$ truncated based on the conditions $-1<\theta <1$ and $0<\theta +\eta <1$.\relax }{figure.caption.2}{}}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {3.1.2}Model Formulation \& Prior Elicitation}{12}{subsubsection.3.1.2}\protected@file@percent }
\newlabel{sec:example1model}{{3.1.2}{12}{Model Formulation \& Prior Elicitation}{subsubsection.3.1.2}{}}
\citation{R2017}
\citation{Borchers2019}
\BKM@entry{id=19,open,dest={73756273756273656374696F6E2E332E312E33},srcline={736}}{4578616D706C65205061746873}
\BKM@entry{id=20,open,dest={73756273756273656374696F6E2E332E312E34},srcline={758}}{507265706F73746572696F7220416E616C79736973206F66204F7065726174696E6720436861726163746572697374696373}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {3.1.3}Example Paths}{13}{subsubsection.3.1.3}\protected@file@percent }
\@writefile{toc}{\contentsline {subsubsection}{\numberline {3.1.4}Preposterior Analysis of Operating Characteristics}{13}{subsubsection.3.1.4}\protected@file@percent }
\newlabel{sec:ex1.1}{{3.1.4}{13}{Preposterior Analysis of Operating Characteristics}{subsubsection.3.1.4}{}}
\BKM@entry{id=21,open,dest={73756273656374696F6E2E332E32},srcline={845}}{506172616C6C656C2054776F2D47726F75702044657369676E20776974682042696E61727920456E64706F696E74}
\BKM@entry{id=22,open,dest={73756273756273656374696F6E2E332E322E31},srcline={846}}{4D6F7469766174696E67204578616D706C65}
\citation{Brunner2020}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.2}Parallel Two-Group Design with Binary Endpoint}{14}{subsection.3.2}\protected@file@percent }
\newlabel{sec:example2}{{3.2}{14}{Parallel Two-Group Design with Binary Endpoint}{subsection.3.2}{}}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {3.2.1}Motivating Example}{14}{subsubsection.3.2.1}\protected@file@percent }
\newlabel{sec:example2motivating}{{3.2.1}{14}{Motivating Example}{subsubsection.3.2.1}{}}
\BKM@entry{id=23,open,dest={73756273756273656374696F6E2E332E322E32},srcline={867}}{4D6F64656C20466F726D756C6174696F6E205C303436205072696F7220456C696369746174696F6E}
\BKM@entry{id=24,open,dest={73756273756273656374696F6E2E332E322E33},srcline={897}}{507265706F73746572696F7220416E616C79736973206F66204F7065726174696E6720436861726163746572697374696373}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {3.2.2}Model Formulation \& Prior Elicitation}{15}{subsubsection.3.2.2}\protected@file@percent }
\newlabel{sec:example2model}{{3.2.2}{15}{Model Formulation \& Prior Elicitation}{subsubsection.3.2.2}{}}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {3.2.3}Preposterior Analysis of Operating Characteristics}{15}{subsubsection.3.2.3}\protected@file@percent }
\newlabel{sec:ex2operatingcharacteristics}{{3.2.3}{15}{Preposterior Analysis of Operating Characteristics}{subsubsection.3.2.3}{}}
\BKM@entry{id=25,open,dest={73656374696F6E2E34},srcline={913}}{5265616C2044617461204578616D706C65}
\BKM@entry{id=26,open,dest={73656374696F6E2E35},srcline={947}}{44697363757373696F6E}
\newlabel{tbl:real-pluto}{{\caption@xref {tbl:real-pluto}{ on input line 935}}{16}{Real Data Example}{table.caption.6}{}}
\@writefile{lot}{\contentsline {table}{\numberline {1}{\ignorespaces Summary characteristics of re-analysis of PLUTO trial. I/F = Interim/Final, $\psi ^{(E)}(\mathcal  {D}_{\text  {obs}})$ = Box's $p$-value using enthusiastic prior, $\omega $ = Enthusiastic mixing weight in adaptive monitoring prior, Efficacy Post Prob = Posterior probability of treatment efficacy.\relax }}{16}{table.caption.6}\protected@file@percent }
\@writefile{toc}{\contentsline {section}{\numberline {4}Real Data Example}{16}{section.4}\protected@file@percent }
\newlabel{sec:realdataexample}{{4}{16}{Real Data Example}{section.4}{}}
\citation{Brunner2020}
\@writefile{toc}{\contentsline {section}{\numberline {5}Discussion}{17}{section.5}\protected@file@percent }
\newlabel{sec:discussion}{{5}{17}{Discussion}{section.5}{}}
\citation{*}
\bibdata{wileyNJD-AMA}
\BKM@entry{id=27,open,dest={73656374696F6E2E35},srcline={1}}{5265666572656E636573}
\bibcite{FDA2006}{{1}{}{{}}{{}}}
\bibcite{Jennison2000}{{2}{}{{}}{{}}}
\bibcite{Spiegelhalter1993}{{3}{}{{}}{{}}}
\bibcite{FDA2017}{{4}{}{{}}{{}}}
\bibcite{FDA_CID}{{5}{}{{}}{{}}}
\bibcite{USCongress2016}{{6}{}{{}}{{}}}
\bibcite{Ventz2015}{{7}{}{{}}{{}}}
\bibcite{Zhu2015}{{8}{}{{}}{{}}}
\bibcite{Stallard2020}{{9}{}{{}}{{}}}
\bibcite{Kopp-Schneider2020}{{10}{}{{}}{{}}}
\bibcite{Zhu2019}{{11}{}{{}}{{}}}
\@writefile{toc}{\contentsline {section}{References\markboth  {\MakeUppercase  {References}}{\MakeUppercase  {References}}}{18}{section.5}\protected@file@percent }
\bibcite{Psioda2018}{{12}{}{{}}{{}}}
\bibcite{LeCam2000}{{13}{}{{}}{{}}}
\bibcite{Nadarajah2005}{{14}{}{{}}{{}}}
\bibcite{Box1980}{{15}{}{{}}{{}}}
\bibcite{Hyams2012}{{16}{}{{}}{{}}}
\bibcite{Rutgeerts2005}{{17}{}{{}}{{}}}
\bibcite{R2017}{{18}{}{{}}{{}}}
\bibcite{Borchers2019}{{19}{}{{}}{{}}}
\bibcite{Brunner2020}{{20}{}{{}}{{}}}
\bibcite{FDA2018}{{21}{}{{}}{{}}}
\@writefile{lof}{\contentsline {figure}{\numberline {3}{\ignorespaces Example paths for the trial described in Section \ref  {sec:example1model}. A, Early stoppage for efficacy. B, Early stoppage for futility.\relax }}{20}{figure.caption.3}\protected@file@percent }
\newlabel{fig:figure2}{{3}{20}{Example paths for the trial described in Section \ref {sec:example1model}. A, Early stoppage for efficacy. B, Early stoppage for futility.\relax }{figure.caption.3}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {4}{\ignorespaces A, Sequential design properties. (SS; mean sample size, PM; posterior mean, CP; coverage probability, (I); interim analysis, (F); final analysis). B, Distribution of final posterior probability given interim stoppage and evidence decrease ($\%$ AGR; percent of agreement between final and interim posterior probabilities relative to $1-\epsilon $ threshold).\relax }}{21}{figure.caption.4}\protected@file@percent }
\newlabel{fig:ex1.1}{{4}{21}{A, Sequential design properties. (SS; mean sample size, PM; posterior mean, CP; coverage probability, (I); interim analysis, (F); final analysis). B, Distribution of final posterior probability given interim stoppage and evidence decrease ($\%$ AGR; percent of agreement between final and interim posterior probabilities relative to $1-\epsilon $ threshold).\relax }{figure.caption.4}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {5}{\ignorespaces A, Enthusiastic prior mixing weight $\omega $ associated with skeptical prior weight minimum $\delta $ in \textup  {\hbox {\mathsurround \z@ \normalfont  (\ignorespaces \ref  {eq:omega}\unskip \@@italiccorr )}} by observed response difference between IP and PC groups, when the PC response rate is fixed at $38\%$ (16/42 responses). B; Summary characteristics of simulated PLUTO trial associated with skeptical prior weight minimum $\delta $ in \textup  {\hbox {\mathsurround \z@ \normalfont  (\ignorespaces \ref  {eq:omega}\unskip \@@italiccorr )}} by risk difference when the PC response rate generated at $39\%$.\relax }}{22}{figure.caption.5}\protected@file@percent }
\newlabel{fig:ex2varyomega}{{5}{22}{A, Enthusiastic prior mixing weight $\omega $ associated with skeptical prior weight minimum $\delta $ in \eqref {eq:omega} by observed response difference between IP and PC groups, when the PC response rate is fixed at $38\%$ (16/42 responses). B; Summary characteristics of simulated PLUTO trial associated with skeptical prior weight minimum $\delta $ in \eqref {eq:omega} by risk difference when the PC response rate generated at $39\%$.\relax }{figure.caption.5}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {6}{\ignorespaces A, Box's p-value by control and treatment sample proportions at the final analysis with 90 subjects when $\delta =0$ is used \textup  {\hbox {\mathsurround \z@ \normalfont  (\ignorespaces \ref  {eq:omega}\unskip \@@italiccorr )}} for the adaptive enthusiastic monitoring prior. B, Posterior probability of efficacy by control and treatment sample proportions.\relax }}{23}{figure.caption.7}\protected@file@percent }
\newlabel{fig:2dheatmaps}{{6}{23}{A, Box's p-value by control and treatment sample proportions at the final analysis with 90 subjects when $\delta =0$ is used \eqref {eq:omega} for the adaptive enthusiastic monitoring prior. B, Posterior probability of efficacy by control and treatment sample proportions.\relax }{figure.caption.7}{}}
\FirstPg{0}\LastPg{23}
\providecommand\NAT@force@numbers{}\NAT@force@numbers
